

Pan-Canadian Competitive Value Price Initiative for Generic Drugs

Alberta prices effective April 1, 2017

In 2013, the Council of the Federation, comprised of Canada's 13 provincial and territorial premiers, announced a price reduction to 18 per cent of the lowest brand price in participating provinces and territories for six drugs for the Pan-Canadian Competitive Value Price Initiative for Generic Drugs. In 2014, 2015 and 2016, a total of 12 additional drugs were added.

This year, a bridging period for the pan-Canadian Pharmaceutical Alliance (pCPA) Generics Initiative was announced effective for April 1, 2017. Under the bridging arrangement, the price of the following molecules will be further reduced from 18 per cent to 15 per cent of the brand reference price: Atorvastatin, Amlodipine, Simvastatin, Pantoprazole, Ramipril and Clopidogrel. More information on the pCPA Generics Initiative can be found at: <http://formulary.drugplan.health.gov.sk.ca/PanCanadian.aspx>.

Through a Pan-Canadian Price Confirmation process, manufacturers have confirmed their ability to supply the drugs included in this Initiative at the prices listed below **as of April 1, 2017** to pharmacies in participating provinces and territories, including Alberta.

New pricing for drugs affected by this Initiative **will become effective immediately on April 1, 2017**. The *Alberta Drug Benefit List (ADBL)* will be updated at that time to reflect the change to the price of each of the drugs and the Least Cost Alternative (LCA) in the interchangeable grouping for these drugs.

A transition or washout period will not apply to drug products in this Initiative. Notification of prices is being provided at this time to allow pharmacies, manufacturers and wholesalers adequate time to adjust inventories and manage stocks.

Please see the below list of drug molecules included in the Pan-Canadian Generic Value Price Initiative for Generic Drugs and the prices for the *ADBL* to be effective on April 1, 2017. Claims submitted for drug products affected by this Initiative, with service dates of April 1, 2017 or greater will be subject to the new LCA price.

AMLODIPINE BESYLATE

2.5 MG (BASE) ORAL TABLET	\$ 0.1150
5 MG (BASE) ORAL TABLET	\$ 0.2014
10 MG (BASE) ORAL TABLET	\$ 0.2990

ATORVASTATIN CALCIUM

10 MG (BASE) ORAL TABLET	\$ 0.2615
20 MG (BASE) ORAL TABLET	\$ 0.3268
40 MG (BASE) ORAL TABLET	\$ 0.3513
80 MG (BASE) ORAL TABLET	\$ 0.3513

... continued from previous page

CITALOPRAM HYDROBROMIDE

10 MG (BASE) ORAL TABLET	\$ 0.1432
20 MG (BASE) ORAL TABLET	\$ 0.2397
40 MG (BASE) ORAL TABLET	\$ 0.2397

CLOPIDOGREL BISULFATE

75 MG (BASE) ORAL TABLET	\$ 0.3946
--------------------------	-----------

DONEPEZIL HYDROCHLORIDE

5 MG ORAL TABLET	\$0.8255
10 MG ORAL TABLET	\$0.8255

EZETIMIBE

10 MG ORAL TABLET	\$0.3260
-------------------	----------

GABAPENTIN

100 MG ORAL CAPSULE	\$ 0.0749
300 MG ORAL CAPSULE	\$ 0.1821
400 MG ORAL CAPSULE	\$ 0.2171

METFORMIN HCL

500 MG ORAL TABLET	\$ 0.0444
850 MG ORAL TABLET	\$ 0.0610

OLANZAPINE

2.5 MG ORAL TABLET	\$ 0.3189
5 MG ORAL TABLET	\$ 0.6379
7.5 MG ORAL TABLET	\$ 0.9568
10 MG ORAL TABLET	\$ 1.2758
15 MG ORAL TABLET	\$ 1.9136
5 MG ORAL DISINTEGRATING TABLET	\$ 0.6434
10 MG ORAL DISINTEGRATING TABLET	\$ 1.2857

continued on next page ...

... continued from previous page

OMEPRAZOLE

20 MG ORAL CAPSULE/SUSTAINED-RELEASE TABLET \$ 0.4117

PANTOPRAZOLE

40 MG ORAL ENTERIC-COATED TABLET \$ 0.3024

QUETIAPINE FUMARATE

25 MG (BASE) ORAL TABLET \$0.0889

100 MG (BASE) ORAL TABLET \$0.2372

200 MG (BASE) ORAL TABLET \$0.4764

300 MG (BASE) ORAL TABLET \$0.6953

RABEPRAZOLE SODIUM

10 MG ORAL ENTERIC-COATED TABLET \$ 0.1204

20 MG ORAL ENTERIC-COATED TABLET \$ 0.2408

RAMIPRIL

1.25 MG ORAL CAPSULE/TABLET \$ 0.1062

2.5 MG ORAL CAPSULE/TABLET \$ 0.1225

5 MG ORAL CAPSULE/TABLET \$ 0.1225

10 MG ORAL CAPSULE/TABLET \$ 0.1551

ROSUVASTATIN CALCIUM

5 MG (BASE) ORAL TABLET \$ 0.2311

10 MG (BASE) ORAL TABLET \$ 0.2437

20 MG (BASE) ORAL TABLET \$ 0.3046

40 MG (BASE) ORAL TABLET \$ 0.3582

continued on next page ...

... continued from previous page

SIMVASTATIN

5 MG ORAL TABLET	\$ 0.1534
10 MG ORAL TABLET	\$ 0.3035
20 MG ORAL TABLET	\$ 0.3751
40 MG ORAL TABLET	\$ 0.3751
80 MG ORAL TABLET	\$ 0.3751

VENLAFAXINE HCL

37.5 MG (BASE) ORAL EXTENDED-RELEASE CAPSULE	\$ 0.1643
75 MG (BASE) ORAL EXTENDED-RELEASE CAPSULE	\$ 0.3285
150 MG (BASE) ORAL EXTENDED-RELEASE CAPSULE	\$ 0.3469

ZOPICLONE

5 MG ORAL TABLET	\$0.1782
7.5 MG ORAL TABLET	\$0.2250

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.677 2017/02

